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ABSTRACT
The aim of the present study was to evaluate subacute toxicity of etimicin sulphate on wistar rat. Results from the present 
study have elucidated that treatment of etimicin sulphate exerts no significant signs of toxicity at any dose level used in the 
study. Physical, biochemical as well as hematological parameters was unaltered throughout the study. Histopathology of all 
organs confirmed no significant alteration at any dose levels. The results of study have suggested there was no obvious 
toxicity observed with the treatment of etimicin sulphate. It was found to be safe alternative for various severe infections.
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INTRODUCTION
Aminoglycoside  antibiotics  have  long  been  used  in 
antibacterial  therapy.  Despite  their  beneficial  effects, 
aminoglycosides  have  considered  nephrotoxic  and  ototoxic 
side  effects.
[1] Streptomycin  was  the  first  aminoglycoside 
introduced  in 1944,  followed  by  neomycin  (1949), 
kanamycin  (1957),  gentamicin  (1963),  tobramycin  (1968), 
amikacin  (1972),  and  netilmicin  in  1975.  Tobramycin, 
gentamicin,  amikacin  and  netilmicin  are  used  in  Gram-
negative bacteraemic patients, while streptomycin is used as 
a  mycobactericidal  agent.  The  incidence  of  nephrotoxicity 
from aminoglycosides has increased from 2 to 3 % in 1969 to 
20 %  in  the  past  decade.  Despite  nephrotoxicity  and 
ototoxicity, the aminoglycosides are continuously being used 
in  clinical  practice  because  of  their  bactericidal  efficacy, 
synergism with beta lactamagents, low cost, limited bacterial 
resistance,  and  a  post-antibiotic  effect.
[2] However, 
netilmicin has low ototoxicity and nephrotoxicity.
[3]
Etimicin sulfate is a new aminoglycoside. It is semi-synthetic 
water-soluble  broad-spectrum antibiotics, is a  derivative  of 
gentamicin C1a, its mechanism is the inhibition  of protein 
synthesis  in  susceptible  strains,  with  efficient,  safe,  wide 
spectrum, less cross-resistance and other characteristics.
[4-5]
It  has  been  shown  that  for  gentamicin-resistant  strains, 
etimicin is still-sensitive; pairs of Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus has good curative 
effect.
[6]
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Scanty  information  is  available  on  the  toxicity  and  safety 
profile of etimycin sulphate drug. We therefore investigated 
whether etimicin sulphate treatment is  associated with any 
kind  of  toxicities  in  preclinical  setting  using  wistar  rat  as 
experimental model.
MATERIALS AND METHODS 
Forty eight  healthy wistar Strain rat (weighing 150-200 g) 
were  divided  into  four  groups (12  animals  in  each  group) 
depending upon the dose of Etimicin. Each group is further 
sub divided into two groups depending on sex of rat having 6 
animals each. Rat were housed in polycarbonate cages with 
bedding of husk, under hygienic conditions and acclimatized 
to the laboratory conditions for a period of seven days prior 
to initiation of dosing. Animals were kept in air conditioned 
rooms with 10-15 air changes per hour, temperature between 
20-24°C  having  12 h  light  and  dark  cycle  and  humidity 
between  30  to  70 %.  Animals  were  given  Nutrilab  brand 
extruded  pelleted  mouse  feed  (Tetragon  Chemie  Pvt.  Ltd. 
Banglore, India) and portable water ad libitum. Animals were
given freshly prepared intravenous injection of Etimicin for 
28  days.  The  mixture  of  Etimicin  was  prepared  in  0.9  % 
NaCl  injection  before  administration  and  was  injected  at 
following dose levels.
Group I       0 mg/kg
Group II     50 mg/kg
Group III    100 mg/kg
Group IV    200 mg/kg
Control  group  was injected  0.9 %  NaCl  only.  Dosing was 
done approximately at the same time on each day. All the 
animals  were  observed  for  physical,  biochemical  and 
hematological  alterations.  Overnight  fasted  animals  were 
sacrificed; blood and tissues samples were collected on 29
th
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Toxicological  Studies, Pune, India  had approved the  study 
protocol. 
Hematological parameters
Hemogram  was  performed  on  ACT  diff-2  Hematolgy 
Analyzer (Beckman Coulter India, Ltd., Mumbai, India).
Biochemical Parameters
Serum Gluatmic Oxaloacetic Transaminase (SGOT), Serum 
Gluatmic Pyruvic Transaminase activities (SGPT), Alkaline 
Phosphatase (ALP), Blood Urea Nitrogen (BUN) and plasma 
sugar levels were estimated on biochemistry analyzer using 
diagnostic kits (Transasia Biomedicals Ltd., Mumbai, India). 
Histopathological examination
Liver, kidney, stomach, Heart and Lungs were removed from 
the sacrificed animals and were preserved in 10 % buffered 
formalin for histological examination.
Statistical analysis
Dunnett's test was used for the evaluation of data and P < 
0.05 accepted as significant.
RESULTS
Physical parameters
No behavioral changes were observed throughout the dosing 
period. No significant change group mean body weight was 
observed in all the groups as compared to control group on 
29
th day. 
Hemogram 
In  male and  female  rat  groups,  no  significant  change  was 
observed in hemoglobin (Hb), red blood cell counts (RBC), 
Rt  (Reticulocyte),  hematocrit  (HCT),  mean  corpuscular 
volume (MCV), mean cell haemoglobin (MCH), mean cell 
corpuscular  hemoglobin  concentration  (MCHC)  E 
(Eosiniophils)  L  (Leukocytes),  M  (Monocytes),  N 
(Neutrophils),  white  blood  cell  (WBC)  counts and  platelet 
counts in all the treated groups as compared to control group 
(Table 1 & 2). 
Biochemical parameters
In  male and  female  rat  groups,  no  significant  change  in 
SGOT, SGPT and  ALP activities  were observed  in all the 
treated groups as compared to respective control group. No 
significant change in Serum proteins and Blood sugar levels 
were observed in both the groups (Table 3 & 4).
Histological examination
No  significant  treatment  related  histopathological  changes 
were observed up to the dose of 200 mg/kg body weight.
DISCUSSION
Aminoglycoside  antibiotics  are  the  most  commonly  used 
antibiotics  worldwide  in  the  treatment  of  Gram-negative 
bacterial  infections 
[7] Aminoglycoside  antibiotics  have  the 
usual  adverse  effects  of  ototoxicity,  renal  toxicity, 
neuromuscular  block,  allergic  reactions.
[8] Their  use  is 
limited  in  the  clinical  practices  due  to  side  effect  of 
ototoxicity and nephrotoxicity.
[9-11] In order to combat these 
issues  related  to  toxicity,  a  new  aminoglycoside  was 
successfully developed named etimicin sulphate.
[12] Etimicin 
is active against most strains of the gram positive and gram 
negative bacteria.
[13-14]
In  present  study  no  significant  physical  changes  were 
observed during the study period of twenty eight days in all 
three  etimicin  sulphate  treatment  groups  as  compared  to 
control. Body growth and increase in body weights of treated 
animals  of either  sex were of  similar pattern as in control 
groups. The organ weight indicated no signs of toxicity.
Aminoglycosides  have  long  been  one  of  the  commonest 
causes  of  drug-induced  nephrotoxicity;  about  10-20  % 
nephrotoxicity  occurs  during  therapeutic  courses.
[7,  15]
Aminoglycoside-induced  nephrotoxicity  is characterized  by 
rises  in  serum  creatinine,  tubular  necrosis  and  marked 
decreases  in  glomerular  filtration  rate  and  in  the 
ultrafiltration  coefficient.
[7,  16] In  addition,  protein 
metabolism, the state  of hydration, and the use of steroids 
influence  the  BUN.
[17] Aminoglycosides  are  nephrotoxic 
because a small proportion of the administered dose (about 5
%)  is  retained  in  the  epithelial  cells  lining  the  S1  and  S2 
segments of the proximal tubules after glomerular filtration.
[18] We also evaluated kidney function related parameters and 
no  significant  differences  were  observed  in  BUN,  glucose 
and proteins with respect to control (Table 3 and 4). 
Blood was evaluated for hematological toxicity of etimicin 
sulphate. Hemogram was estimated and results had shown no 
significant  changes  on  blood  cell  count  and  haemoglobin. 
The  MCH  and  MCHC  in  etimicin  sulphate  treated  group 
were similar to control. MCV was observed slightly lower 
with  maximum  dose  in  both  sex  which  was  statistically 
insignificant (Table 1 and 2). 
Hepatotoxicity  implies  chemical-driven  liver  damage. 
Chemicals  often  cause  subclinical  injury to  liver  which 
manifests only as abnormal liver enzyme tests.
[19] The first 
sign of damage to the liver is an increase in liver enzyme 
levels in the blood. When the liver is damaged, its enzymes 
are released into  the bloodstream,  where the levels  can  be 
measured by blood tests. Aminogycosides are also known to 
cause  hepatotoxicity  by  increasing  oxidative  stress.  To 
evaluate  effect  of  etimicin  on  liver  damage,  liver  specific 
parameters  were  estimated.  It  was  found  that  etimicin 
sulphate  had  not  altered  ALP,  SGOT  and  SGPT  activities
significantly, which confirmed no hepatotoxicity by Etimicin 
sulphate treatment of either sex as compared to the respective 
control group (Table 3 and 4). Histopathological analysis had 
shown no signs of toxicity in any of the organ in treatment
groups  as  compared  to  etimicin  sulphate.  Thus 
histopathological  studies  also  confirmed the  safety  data  of 
other  physiological, biochemical  and  heamatological 
parameters after etimicin sulphate treatment.
Table 1: Effect of sub acute dose of Etimicin on hemogram in male wistar rat
Parameters Control Etimicin (50 mg/kg) Etimicin (100 mg/kg) Etimicin (200 mg/kg)
Haemoglobin (g %) 15.54±1.55 15.55±1.16 15.20±1.88 13.58±1.76
Total RBC(X10
6/cmm) 6.07±0.82 6.28±0.89 6.00±0.96 5.85±1.36
Rt (%) 1.05±0.22 1.18±.26 1.50±0.43 1.53±.42
HCT (%) 46.35±4.57 46.53±3.83 44.72±5.71 40.73±5.38
MCV (µm
3) 77.40±11.68 75.09±10.41 77.11±21.78 73.41±20.50
MCH (pg) 26±4.41 25.19±4.26 26.23±7.49 24.51±6.92
MCHC (%) 33.65±1.05 33.45±1.30 34.02±.80 33.38±1.33
Platelets (X10
5/cmm) 8.52±0.73 7.90±1.07 7.85±1.06 7.33±1.18
TotalWBC(X10
3/cmm) 5.58±0.82 5.87±0.98 5.89±0.79 5.83±0.92
Differential %
N 20.50±1.87 22.50±1.87 22.17±1.47 22.50±1.87
L 76.17±1.94 76±2.68 76.00±2.61 76±2.45
E 2.67±1.21 1.83±0.98 1.83±0.98 1.83±0.75
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Table 2: Effect of sub acute dose of Etimicin on hemogram in female wistar rat
Parameters Control Etimicin (50 mg/kg) Etimicin (100 mg/kg) Etimicin (200 mg/kg)
Haemoglobin (g %) 15±1.93 15.03±1.23 13.77±2.27 14.85±2.42
Total RBC(X10
6/cmm) 5.52±0.85 5.22±0.74 5.83±1.01 5.98±0.78
Rt (%) 1.12±0.28 1.43±0.35 1.48±0.51 1.48±0.51
HCT (%) 44.07±6.54 44.53±3.93 41.77±6.01 43.53±7.09
MCV (µm
3) 81.44±16.91 86.03±9.80 74.14±20.67 74.75±20.42
MCH (pg) 27.75±5.47 29.12±3.35 24.53±7.53 25.50±7.06
MCHC (%) 34.02±1.04 33.86±0.83 32.89±1.08 34.13±1.05
Platelets (X10
5/cmm) 8.19±1.07 8.35±1.01 7.60±1.18 7.62±.91
TotalWBC(X10
3/cmm) 5.95±0.99 6.18±0.70 5.55±1.08 4.98±0.65
Differential %
N 21.33±2.16 22.50±1.87 22±1.90 22±1.41
L 77.17±2.86 76±2.10 76.67±2.94 76±2.61
E 2.17±1.17 1.83±1.47 1.83±0.98 2.33±1.21
M 0.33±0.52 0.67±0.52 0.67±0.82 0.33±0.52
Table 3: Effect of sub acute dose of Etimicin on biochemical parameters in male wistar rat
Group I Group II Group III Group IV
Total Protein (g%) 6.37±1.30 6.32±.89 6.15±1.32 5.70±.87
BUN (mg%) 21.83±2.32 22.67±3.08 24.33±3.93 26.33±5.68
SGPT (IU/L) 49.67±8.16 54±9.38 59±8.10 59.33±12.55
SGOT (IU/L) 93.83±9.04 96.83±9.28 99.33±13.91 102.50±9.93
SAP (IU/L) 270.83±58.56 277.00±65.29 342.50±84.76 340.17±112.52
Blood Sugar (mg %) 95.17±5.85 92.67±7.37 96.67±5.24 96±7.56
Data is presented as mean ± Standard deviation (n=6 in each group)
Table 4: Effect of sub acute dose of Etimicin on biochemical parameters in female wistar rat
Group I Group II Group III Group IV
Total Protein (g %) 6.03±1.01 6.27±1.24 6.02±1.05 6.08±1.02
BUN (mg %) 20.83±2.32 21.83±2.14 25.67±3.72 25.83±5.27
SGPT (IU/L) 51.17±10.11 55.67±11.89 61.33±7.58 59.33±10.82
SGOT (IU/L) 94±6.16 103.50±11.50 97.83±9.33 102.50±12.96
SAP (IU/L) 256.33±78.38 301±62.65 332.17±96.12 330.50±91.52
Blood Sugar (mg %) 95.33±6.56 95.50±7.23 96.67±6.50 97.33±5.47
Data is presented as mean ± Standard deviation (n=6 in each group)
In conclusion, our results provide support for safety profile of 
this potential drug. The data suggest that Etimicin sulphate is 
safe even at maximum dose level and no significant effect 
was  observed  on  any  of  physiological  and  biochemical 
parameters.  Thus,  etimicin  sulfate  injection  is  an effective 
safe antibiotic and possessing widely clinical application and 
worth for wide use.
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